RT Journal Article
SR Electronic
T1 The gut microbiota and host health: a new clinical frontier
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 330
OP 339
DO 10.1136/gutjnl-2015-309990
VO 65
IS 2
A1 Marchesi, Julian R
A1 Adams, David H
A1 Fava, Francesca
A1 Hermes, Gerben D A
A1 Hirschfield, Gideon M
A1 Hold, Georgina
A1 Quraishi, Mohammed Nabil
A1 Kinross, James
A1 Smidt, Hauke
A1 Tuohy, Kieran M
A1 Thomas, Linda V
A1 Zoetendal, Erwin G
A1 Hart, Ailsa
YR 2016
UL http://gut.bmj.com/content/65/2/330.abstract
AB Over the last 10–15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new ‘omic’ technologies that have facilitated large-scale analysis of the genetic and metabolic profile of this microbial community, revealing it to be comparable in influence to a new organ in the body and offering the possibility of a new route for therapeutic intervention. Moreover, it might be more accurate to think of it like an immune system: a collection of cells that work in unison with the host and that can promote health but sometimes initiate disease. This review gives an update on the current knowledge in the area of gut disorders, in particular metabolic syndrome and obesity-related disease, liver disease, IBD and colorectal cancer. The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.